2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4028 Final efficacy and safety outcomes of subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma (NDMM) after transplant: Auriga study

Kenneth H. Shain, MD, PhD, Larry D Anderson Jr, MD, PhD2, Laahn Foster, MD3, Alfred Chung, MD4, Chakra P Chaulagain, MD5, Erin M. Pettijohn6, Andrew J. Cowan, MD7, Caitlin Costello, MD8, Sarah M. Larson, MD9, Doug W. Sborov, MD, MS10, Rebecca Silbermann, MD11, Peter Voorhees, MD12, Mitul Gandhi, MD13, Maria Krevvata14, Mai Ngo15, Sharmila Patel, PhD16, Jennifer Phillips17, Vipin Khare, MD18, Thomas S. Lin, MD, PhD19, Ashraf Badros, MD20
1 Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States
2 Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
3 Division of Hematology Oncology, University of Virginia, Charlottesville, Virginia, United States
4 Department of Medicine, University of California San Francisco, San Francisco, California, United States
5 Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, Florida, United States
6 Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
7 Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States
8 Moores Cancer Center, University of California San Diego, La Jolla, California, United States
9 Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
10 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
11 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
12 Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, North Carolina, United States
13 Virginia Cancer Specialists, Warrenton, Virginia, United States
14 Johnson & Johnson, Spring House, Pennsylvania, United States
15 Cytel, Cambridge, Massachusetts, United States
16 Johnson & Johnson, Horsham, Pennsylvania, United States
17 Johnson & Johnson, Horsham, Pennsylvania, United States
18 Johnson & Johnson, Horsham, Pennsylvania, United States
19 Johnson & Johnson, Horsham, Pennsylvania, United States
20 Greenbaum Cancer Center; University of Maryland, Baltimore, Maryland, United States

Introduction: Lenalidomide (R) maintenance is a standard of care following autologous stem cell transplant (ASCT) for patients with NDMM. In the primary analysis of the phase 3 AURIGA study (NCT03901963), addition of subcutaneous daratumumab (DARA SC) to R (D-R) maintenance improved minimal residual disease (MRD)-negative (neg) conversion and reduced the risk of disease progression or death by 45% vs R alone. We report long-term efficacy and safety results, along with key subgroup outcomes, from AURIGA after extended follow-up.

Methods: Eligible patients had NDMM; were aged 18-79 yrs; had received ≥4 induction cycles; were in very good partial response or better and were MRD positive (10–5 threshold per NGS) following ASCT; had no prior anti-CD38 therapy; and were enrolled within 6 mos of ASCT. Patients were randomized 1:1 (stratified by cytogenetic risk) to 28-day cycles of R maintenance ± DARA SC for 36 cycles or until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint of MRD-neg (10–5) conversion by 12 mos from start of maintenance was previously reported.

Results: Overall, 200 patients were randomized (D-R: n=99; R: n=101). Baseline demographics and clinical characteristics were generally balanced between groups. Median age at baseline was 62 (range 35-78) yrs; 24.3% of patients had ISS stage III; 20.4% had high cytogenetic risk (del[17p], t[4;14], or t[14;16]) at diagnosis; and 34.1% had revised high cytogenetic risk (also t[14;20] or gain/amp[1q]) at diagnosis. The median number of maintenance cycles received was 36 for D-R and 27 for R, with 63.5% and 41.8% of patients completing all 36 cycles, respectively.

At a median follow-up of 58.2 mos, overall MRD-neg conversion rates favored D-R vs R at both the 10–5 (61.6% vs 29.7%; OR 3.92; P<0.0001) and 10–6 (37.4% vs 13.9%; OR 3.76; P=0.0002) thresholds. MRD-neg conversion rates with complete response or better were also higher for D-R vs R at 10–5 (58.6% vs 24.8%; OR 4.47; P<0.0001) and 10–6 (36.4% vs 10.9%; OR 4.76; P<0.0001). Across subgroups, MRD-neg (10–5) conversion rates trended higher for D-R vs R (age ≥65 yrs: 65.8% vs 27.5%; Black race: 80.0% vs 33.3%; ISS stage III: 78.3% vs 13.0%; standard cytogenetic risk: 65.1% vs 31.8%; high cytogenetic risk: 50.0% vs 20.0%; revised high cytogenetic risk: 62.5% vs 20.0%). D-R maintenance led to improved rates of sustained MRD neg lasting ≥12 mos vs R at both 10–5 (35.4% vs 8.9%; OR 5.66; P<0.0001) and 10–6 (22.2% vs 2.0%; OR 14.26; P<0.0001), and lasting ≥24 mos at both 10–5 (27.3% vs 5.0%; OR 7.19; P<0.0001) and 10–6 (14.1% vs 2.0%; OR 8.29; P=0.0015).

Improvement in progression-free survival (PFS) per computerized algorithm was statistically significant for D-R vs R (HR 0.60; P=0.0336); median PFS was not reached for D-R vs 54.0 mos for R, and estimated 60-mo PFS rates were 60.0% for D-R and 49.0% for R. Across subgroups, PFS showed a trend toward improvement with D-R vs R (age ≥65 yrs: HR 0.73; Black race: HR 0.59; ISS stage III: HR 0.29; standard cytogenetic risk: HR 0.62; high cytogenetic risk: HR 0.53; revised high cytogenetic risk: HR 0.53). Median overall survival (OS) was not reached for both groups (HR 0.54; P=0.1188); estimated 60-mo OS rates numerically favored D-R (88.7% vs 80.2% for R).

Overall, 75.0% of D-R patients and 73.5% of R patients experienced grade 3/4 treatment-emergent adverse events (TEAEs); neutropenia (49.0% vs 45.9%) and leukopenia (10.4% vs 7.1%) were the most common in both groups. Grade 3/4 infections occurred in 21.9% of D-R patients and 14.3% of R patients. Serious TEAEs occurred in 33.3% of D-R patients and 25.5% of R patients. TEAEs led to discontinuation of any study treatment in 16.7% of D-R patients (DARA SC 10.4%; R 16.7%) and 11.2% of R patients. Fatal TEAEs occurred in 2 D-R and 2 R patients; all were due to infections/sepsis. Incidences of TEAEs were generally consistent across age and race subgroups. Overall, second primary malignancy rates were comparable for D-R (11.5%) and R (10.2%) patients, with hematologic malignancies occurring in 3.1% of D-R patients and 5.1% of R patients.

Conclusions: With a median follow-up of nearly 5 yrs, D-R maintenance continued to demonstrate superior outcomes, including higher MRD-neg conversion and sustained MRD-neg rates at the 10–5 and 10–6 thresholds. Addition of DARA SC to R maintenance also led to significant improvement in PFS and a trend toward longer OS, with no new safety signals observed.

Kenneth H. Shain, MD, PhD: Adaptive - Honoraria; AbbVie Inc. - Honoraria; Kite - Honoraria; Bristol Myers Squibb - Honoraria; Regeneron - Honoraria; Sebia - Honoraria; Takeda - Honoraria; Sanofi - Honoraria; Amgen - Honoraria; Arcellx - Honoraria; GSK - Honoraria; Janssen - Honoraria; Karyopharm Therapeutics - Research Funding; Pfizer - Research Funding; AbbVie Inc. - Research Funding